2nd ESCMID Conference on The Impact of Vaccines on Public Health
22 - 24 March 2013, Prague, Czech Republic
Conference material
All conference materials (slides, webcasts) can be found in the ESCMID Online Lecture Library
Conference Objectives
As part of its multifaceted approach to infections, ESCMID strives to promote vaccination and worries that the current lack of correct information among both lay public and healthcare providers might seriously undermine the efficacy of current and future vaccine campaigns. This conference will bring together world-leading experts to debate the many-sided correlations between vaccines, medicine and society at the dawn of the third millennium.
Conference Venue
Ambassador Congress Hall
Vaclavske namesti 5–7
11124 Prague, Czech Republic
Target Audience
Specialists or physicians in training in infectious diseases, clinical microbiology, hygiene, public health, vaccinology and other disciplines dealing with all aspects of vaccination.
Registration Procedure
Please download the registration form (see link on the right) and return it to the conference secretariat.
Registration Fee
Members of ESCMID and Affiliated Societies
- Before and on 8 January 2013: EUR 500
- After 8 January 2013: EUR 600
All others
- Before and on 8 January 2013: EUR 700
- After 8 January 2013: EUR 800
The registration fee includes the scientific sessions, printed conference material, lunches and coffee breaks, but not travel and accommodation costs.
Scientific Secretariat
Giuseppe Cornaglia
Dept. of Pathology and Diagnostics
University of Verona
Phone +39 045 802 71 96
Fax +39 045 802 71 01
Giuseppe Cornaglia
Conference Secretariat
ICO
Marco Moschin
Via Lorenzo Marcello 32
30126 Lido di Venezia
Italy
Phone +39 041 52 62 530
Fax +39 041 52 71 129
Conference Secretariat
Scientific Programme
Friday, 22 March 2013
08.15 | Registration |
The role of WHO-Europe/ECDC Chairs: Giuseppe Cornaglia & Jaroslav Blahos | |
---|---|
09.00 | The role of WHO-Europe. Dina Pfeifer |
09.30 | The role of ECDC. Piotr Kramarz |
10.00 | Coffee break |
Paediatric and adolescent vaccination Chairs: Dina Pfeifer & Sarka Nemeckova | |
---|---|
10.30 | Multivalent paediatric vaccines. Susanna Esposito |
11.00 | The possible evolution of paediatric influenza vaccination in Europe. Kari Johansen |
11.30 | Measles elimination and the interruption of indigenous transmission. Dina Pfeifer |
12.00 | Chickenpox vaccination: a laboured take off. Paloma Carrillo-Santisteve |
12.30 | Lunch |
Vaccines for adults Chairs: Vincenzo Bronte & Roman Chlibek | |
---|---|
14.00 | Lifelong vaccination as a key disease - prevention strategy. Paolo Bonanni |
14.30 | Influenza immunisation in elderly. Patricia Blank |
15.00 | Pertussis boostering in adults. Maarten J. Postma |
15.30 | Coffee break |
Vaccines and women: more than a gender issue Chairs: Pierluigi Lopalco & Eva Hamsikova | |
---|---|
16.00 | The potential role of GBS vaccination: overall value and the hurdles of prenatal programmes. Paul Heath |
16.30 | Eliminating rubella and preventing congenital rubella syndrome in Europe. Mark Muscat |
17.00 | Implementing HPV vaccination: where do we stand now? Mario Poljak |
17.30 | Next-generation HPV vaccines: challenges and perspective. Elmar Joura |
Saturday, 23 March 2013
07.30 | Registration |
Hepatitis Chairs: Mario Poljak & Petr Pazdiora | |
---|---|
08.00 | Hepatitis B vaccination in Western European countries. Pierre Van Damme |
08.30 | Hepatitis A vaccination: can we do better? Dina Pfeifer |
09.00 | Hepatitis E vaccines: phase II and phase III trials. Wai Kuo Shih & Ning-Shao Xia |
09.30 | Hepatitis C vaccines: myth or reality? Sergio Abrignani |
10.00 | Coffee break |
Vaccines for encephalitis and viral haemorrhagic fevers Chairs: Raul E. Isturiz & Lenka Strakova | |
---|---|
10.30 | Tetravalent Dengue vaccine – from research to phase III. Ragnar Norrby |
11.00 | Japanese Encephalitis vaccines. Katrin Dubischar-Kastner |
11.30 | Recombinant DNA-derived vaccines for VHF. Connie S. Schmaljohn |
12.00 | Tick borne encephalitis. Franz X. Heinz |
12.30 | Lunch |
Novel vaccine targets Chairs: Karen Kotloff & Frantisek Stejskal | |
---|---|
13.30 | CMV vaccine: phase II trial results. Christoph Steininger |
14.00 | New and candidate vaccines for gastrointestinal infections. Karen Kotloff |
14.30 | Norovirus vaccine: first results. Timo Vesikari |
15.00 | Vaccines to constrain antimicrobial resistance. Ron Dagan |
15.30 | Malaria vaccine research and development: Status and first results from the ongoing phase 3 trial of the RTS,S candidate. Joe Cohen |
16.00 | Coffee break |
Pneumococcal vaccines and their implementation strategy Chairs: Ron Dagan & Roman Prymula | |
---|---|
16.30 | Pneumococcal infection in adults: burden of disease. Gernot Rohde |
17.00 | Pneumococcal vaccination in the EU: current status and perspectives. Bernard Fritzell |
17.30 | Role of vaccines in preventing pneumococcal diseases. Stefano Aliberti |
18.00 | Pneumococcal vaccination: do we need a new implementation strategy? Pavla Krizova |
Sunday, 24 March 2013
07.30 | Registration |
Novel vaccines for old diseases Chairs: Rino Rappuoli & Jana Prattingerova | |
---|---|
08.00 | Flu vaccination facing flu virus mutability. Albert Osterhaus |
08.30 | Innovative strategies for meningococcal vaccines. Mariagrazia Pizza |
09.00 | New vaccines against tuberculosis. Giovanni Delogu |
09.30 | A vaccine for Staphylococcus aureus? Richard A. Proctor |
10.00 | Coffee break |
Towards the future: technological challenges and vaccine policies Chairs: Giovanni Rezza & Pavla Krizova | |
---|---|
10.30 | From genomics to structural vaccinology. Rino Rappuoli |
11.00 | The rationale for conjugate vaccines. Dennis Kasper |
11.30 | Actual immunisation coverage throughout Europe: are existing data sufficient? Pierluigi Lopalco |
12.00 | Emerging economies from consumers to new donor countries. Suresh Jadhav |
12.30 | Contrasting the anti-vaccine movements. Robb Butler |
13.00 | Lunch |